Cargando…

Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer

Tyrosine kinases (TKs) play a significant role in cancerogenesis and cancer cell function. Initial developments in this field go back to the early 80s, but the success story really started with the selective BCR-ABL inhibitor, imatinib. Owing to the cancer-driving role of BCR-ABL in chronic myeloid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Na, Il-Kang, le Coutre, Philipp
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567050/ https://www.ncbi.nlm.nih.gov/pubmed/26401097 http://dx.doi.org/10.4137/BMI.S22432

Ejemplares similares

Reaching Un-Drugable Intracellular Targets with the Long Arm of Antibodies
por: Scheinberg, David A., et al.
Publicado: (2013)

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
por: Amatu, Alessio, et al.
Publicado: (2015)

Chemical Proteomic Analysis Reveals the Drugability of the Kinome of Trypanosoma brucei
por: Urbaniak, Michael D., et al.
Publicado: (2012)

Prognostic Importance and Therapeutic Implications of PAK1, a Drugable Protein Kinase, in Gastroesophageal Junction Adenocarcinoma
por: Li, Zongtai, et al.
Publicado: (2013)

Long‐term observation of the frequency of secondary colorectal cancer and other malignancies in tyrosine kinase inhibitor treated chronic myeloid leukemia patients and controls
por: Winkelmann, Nina, et al.
Publicado: (2022)

Tyrosine kinase signalling in breast cancer
por: Hynes, Nancy E
Publicado: (2000)

Glutamine Synthetase Drugability beyond Its Active Site: Exploring Oligomerization Interfaces and Pockets
por: Moreira, Cátia, et al.
Publicado: (2016)

Assessment of the drugability of initial malaria infection through miniaturized sporozoite assays and high-throughput screening
por: Miglianico, Marie, et al.
Publicado: (2023)

Rhomboids and regulation of receptor tyrosine kinase ligands shedding
por: Karachaliou, Niki, et al.
Publicado: (2018)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
por: Le, Xiuning, et al.
Publicado: (2023)

Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer
por: Liu, Bing, et al.
Publicado: (2021)

Progranulin and the receptor tyrosine kinase EphA2, partners in crime?
por: Chitramuthu, Babykumari, et al.
Publicado: (2016)

Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach
por: de Jong, Mathilde R. W., et al.
Publicado: (2018)

Identification of Natural Inhibitors Against SARS-CoV-2 Drugable Targets Using Molecular Docking, Molecular Dynamics Simulation, and MM-PBSA Approach
por: Kushwaha, Prem Prakash, et al.
Publicado: (2021)

Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
por: K. Bhanumathy, Kalpana, et al.
Publicado: (2021)

Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib
por: Agwa, Eberechi S, et al.
Publicado: (2014)

The dosing of ibrutinib and related Bruton’s tyrosine kinase inhibitors: eliminating the use of brute force
por: Ratain, Mark J., et al.
Publicado: (2022)

Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2022)

Species-Specific Interactions of Src Family Tyrosine Kinases Regulate Chlamydia Intracellular Growth and Trafficking
por: Elwell, Cherilyn A., et al.
Publicado: (2011)

cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation?
por: Normanno, Nicola, et al.
Publicado: (2020)

Tyrosine kinase – Role and significance in Cancer
por: Paul, Manash K., et al.
Publicado: (2004)

Targeting Tyrosine Kinases and Autophagy in Prostate Cancer
por: Kung, Hsing-Jien
Publicado: (2010)

Receptor Tyrosine Kinase-Targeted Cancer Therapy
por: Yamaoka, Toshimitsu, et al.
Publicado: (2018)

Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors – assessment of intra-tumour heterogeneity
por: Stühler, Viktoria, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
por: Weber, Alexander N. R., et al.
Publicado: (2017)

Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus
por: Patsatsi, Aikaterini, et al.
Publicado: (2021)

Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: Indian perspective
por: Ghosh, K
Publicado: (2022)

Receptor tyrosine kinases: role in cancer progression
por: Sangwan, V., et al.
Publicado: (2006)

Establishing the role of tyrosine kinase 2 in cancer
por: Übel, Caroline, et al.
Publicado: (2013)

PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells
por: Glodkowska-Mrowka, E, et al.
Publicado: (2016)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

ALK: a tyrosine kinase target for cancer therapy
por: Holla, Vijaykumar R., et al.
Publicado: (2017)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

Tyrosine Kinases in Cancer
por: Blau, Olga, et al.
Publicado: (2015)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

Role of the Brk tyrosine kinase in breast cancer progression
por: Harvey, AJ, et al.
Publicado: (2006)

The ErbB receptor tyrosine kinases and their roles in cancer
por: Hynes, NE
Publicado: (2003)

The role of RICTOR downstream of receptor tyrosine kinase in cancers
por: Jebali, Ahlem, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cvni4gr3ka0sf85sukqt36j7um